Synbiotic Composition for GLP-1 Deficiency and Weight Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing weight loss drugs are not effective for all obese subjects, particularly those with glucagon-like peptide-1 (GLP-1) deficiency, and there is a need for compositions that can prevent and treat obesity-related diseases.
Innovation Solution
A synbiotic composition comprising lychee polyphenols, probiotics (Bifidobacterium animalis BCRC910645 and Bifidobacterium longum BCRC910812), and methionine is administered to increase GLP-1 levels, which includes additional ingredients like indigestible maltodextrin, fructooligosaccharide, isomalto-oligosaccharide, and rice bran concentrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing weight loss drugs are used, then weight loss may be achieved in some subjects, but they are ineffective for obese subjects with GLP-1 deficiency
Solution Approach 1:
The patent changes the biochemical parameter of GLP-1 levels in the body by administering a synbiotic composition that directly or indirectly increases GLP-1 secretion. This addresses the root cause (GLP-1 deficiency) rather than just treating symptoms, making the treatment effective for subjects who specifically have GLP-1 deficiency-related obesity.
Solution Approach 2:
The patent uses a composite synbiotic composition containing multiple components (lychee polyphenols, probiotics, prebiotics, and methionine) that work synergistically. The probiotics ferment the prebiotics to produce metabolites that stimulate GLP-1 secretion, creating a multi-mechanism approach that improves both reliability and adaptability.
2Reliability
If a synbiotic composition is administered to increase GLP-1 levels, then GLP-1 deficiency is treated, but the composition complexity increases
Solution Approach 1:
The patent segments the treatment approach into distinct functional components: lychee polyphenols (direct GLP-1 secretion stimulator), probiotics (GLP-1 secretion stimulation via fermentation), prebiotics (substrate for probiotics), and methionine (amino acid supplement). Each component has a specific function, and together they create a synergistic effect that justifies the complexity.
Solution Approach 2:
The patent introduces probiotics as an intermediary that ferments prebiotics to produce metabolites which then stimulate GLP-1 secretion. This multi-step intermediary process allows for controlled and sustained GLP-1 elevation, making the complex composition worthwhile for treating GLP-1 deficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synbiotic composition effectively increases GLP-1 levels, aiding in weight management and treating GLP-1 deficiency, with significant improvements observed in both animal and human trials.
Implementation Method 1
The synbiotic composition comprises: lychee polyphenols; probiotics, wherein the probiotics comprises Bifidobacterium animalis BCRC910645, Bifidobacterium longum BCRC910812, or a combination thereof
Data Source
AI summary
A method of increasing glucagon-like peptide-1, including administering to a subject in need thereof an effective amount of synbiotic composition including lychee polyphenols, probiotics and methionine. Probiotics includes Bifidobacterium animalis BCRC910645, Bifidobacterium longum BCRC910812, or a combination thereof for increasing glucagon-like peptide-1. Also provided is a method of preventing or treating glucagon-like peptide-1 deficiency, including administering to a subject in need thereof an effective amount of synbiotic composition as above mentioned.